A

Aurinia Pharmaceuticals
D

AUPH

8.20000
USD
0.00
(0.00%)
مغلق
حجم التداول
48,260
الربح لكل سهم
1
العائد الربحي
-
P/E
205
حجم السوق
1,120,500,710
أصول ذات صلة
A
ACAD
0.355
(2.44%)
14.905 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
A
ARRY
-0.13000
(-2.53%)
5.01000 USD
C
CRIS
-0.04000
(-1.61%)
2.45000 USD
E
ESPR
0.10240
(10.47%)
1.08000 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
V
VKTX
0.775
(2.71%)
29.360 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: Aurinia Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.